<code id='0B0BCCA6A8'></code><style id='0B0BCCA6A8'></style>
    • <acronym id='0B0BCCA6A8'></acronym>
      <center id='0B0BCCA6A8'><center id='0B0BCCA6A8'><tfoot id='0B0BCCA6A8'></tfoot></center><abbr id='0B0BCCA6A8'><dir id='0B0BCCA6A8'><tfoot id='0B0BCCA6A8'></tfoot><noframes id='0B0BCCA6A8'>

    • <optgroup id='0B0BCCA6A8'><strike id='0B0BCCA6A8'><sup id='0B0BCCA6A8'></sup></strike><code id='0B0BCCA6A8'></code></optgroup>
        1. <b id='0B0BCCA6A8'><label id='0B0BCCA6A8'><select id='0B0BCCA6A8'><dt id='0B0BCCA6A8'><span id='0B0BCCA6A8'></span></dt></select></label></b><u id='0B0BCCA6A8'></u>
          <i id='0B0BCCA6A8'><strike id='0B0BCCA6A8'><tt id='0B0BCCA6A8'><pre id='0B0BCCA6A8'></pre></tt></strike></i>

          Home / knowledge / fashion

          fashion


          fashion

          author:focus    Page View:6346
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In